The role of flumazenil infusion in the treatment of benzodiazepine withdrawal

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 28 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flumazenil (Primary)
Indications Substance withdrawal syndrome
Focus Proof of concept; Therapeutic Use
Sponsors Go Medical Industries

Most Recent Events

01 Jul 2022 Results published in the Drug and Alcohol Dependence
04 Mar 2022 Actual date of last participant enrolled is 18 April 2019 according to Australian New Zealand Clinical Trials Registry record.
04 Mar 2022 Status changed from recruiting to discontinued.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight